AKTX - Company ID 0001541157
The table below shows Akari Therapeutics Plc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $367.88K | $607.68K | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.81M | $6.98M | $5.45M | $3.92M | $9.13M | $8.82M |
| SG&A | $9.28M |
Akari Therapeutics Plc reported annual revenue of $367.88K for fiscal year 2023. That is down 39.5% from $607.68K in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $9.66M |
| $11.36M |
| $13.53M |
| $8.08M |
| $9.16M |
| Operating income | -$17.27M | -$21.64M | -$16.81M | -$11.85M | -$17.21M | -$17.98M |
| Income tax | -$1.00M | $0.00 | $0.00 | -$74.00K | $0.00 | $0.00 |
| Net income | -$17.30M | -$19.80M | -$10.01M | -$13.09M | -$17.42M | -$17.08M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | -$0.74 | $0.00 | -$0.01 |